The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Allogene Therapeutics, Inc. Common Stock 019770106 26,829 1,798,163 SH   SOLE   1,798,163 0 0
Centessa Pharmaceuticals plc Ordinary Shares 152309100 44,272 3,931,818 SH   SOLE   3,931,818 0 0
Dyne Therapeutics, Inc. Common Stock 26818M108 35,195 2,960,046 SH   SOLE   2,960,046 0 0
Homology Medicines, Inc. Common Stock 438083107 2,806 770,845 SH   SOLE   770,845 0 0
Kinnate Biopharma, Inc. Common Stock 49705R105 48,685 2,747,433 SH   SOLE   2,747,433 0 0
Kronos Bio, Inc. Common Stock 50107A104 37,581 2,765,314 SH   SOLE   2,765,314 0 0
LianBio Ordinary Shares 53000N108 14,058 2,282,084 SH   SOLE   2,282,084 0 0
Praxis Precision Medicines, Inc. Common Stock 74006W108 57,905 2,939,329 SH   SOLE   2,939,329 0 0